Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why This Obesity Drugmaker's Prescription Data Tells Only Half the Story

By Max Macaluso - Apr 22, 2013 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NASDAQ: VVUS

VIVUS, Inc.

Vivus released prescription data for its obesity drug Qsymia last week, but its earnings report is more important.

As biotech investors continue to wait for Arena Pharmaceuticals to launch its obesity drug Belviq, pharmaceutical company Vivus (VVUS) has been trying to ramp up sales for its rival drug Qsymia. The company's slow drug launch has been the topic of much debate in past quarters, but it recently reported that its total number of prescriptions shipped in March were 42% greater than scripts in January. Should investors be excited about this result, or will the real catalyst for this stock be its upcoming earnings report for the first quarter of 2013? Health-care analyst Max Macaluso sheds light on this topic in the following video.

Stocks Mentioned

VIVUS, Inc.

VVUS

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

The 3 Most Disappointing Drug Launches of All Time

Why Vivus Inc Plummeted Today

Forget About Ebola Stocks and Invest in This Instead

Despite the CDC's Best Efforts, This Disease Just Hit Record Levels

Why VIVUS, Inc. Stock Descended 14% in December

Motley Fool Returns

Market-beating stocks from our award-winning service.

Stock Advisor Returns

332%

S&P 500 Returns

118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.